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Challenges to Translation and the Hippocratic
Oath by Premature Termination of Spinal Cord
StemCell–Based Trials
Untimely termination of clinical trials owing to strate-
gic corporate considerations (30%)1 or futility analysis
(50%)1account formostprematurelydiscontinuedstud-
ies, and spinal cord injury (SCI) trials are no exception
(Figure).2 In this commentary,weadvocate for clear ter-
mination rules, including an orderly exit plan, as a pre-
requisite for regulatoryapproval tooptimizesafeandef-
fective clinical translation. Invasive cell transplant trials
inSCI requireexcellentpreclinical andclinical safetyand
efficacy data, pioneering spirit, and intensive resource
investment. However, premature termination without
an orderly exit plan produces harmful consequences
worthy of discussion.
The Proneuron Phase 2 Autologous Incubated
Macrophage Study was suspended owing to business
considerations after 50 of 61 patients with complete
paralysis (C5 motor/C4 sensory −T11) were randomized
between 2003 and 2009 (1816 prescreened and
screened).2 The company website indicated that clini-
cal follow-up was intended for patients already
enrolled in the study, but confirmation could not be
found either through website updates or subsequent
publications.
The Geron Phase 1 Study of GRNOPC1 (human em-
bryonic stem cell–derived oligodendrocyte progeni-
tors) introduced stem cell transplantation in patients
with complete lower-body paralysis within 7 to 14 days
post-SCIwith enormous publicity but enrolled only 5 of
10 patients over 11 months before prematurely termi-
nating thestudy in2011.Within the last6months,2 trials
to prematurely terminate were the Stem Cells Inc Hu-
man Central Nervous System Stem Cells Phase 2 Study
in cervical SCI and the consecutive Long-Term Fol-
low-Up Study investigating human, fetal-derived neu-
ral stem cells in thoracic SCI.3 Both studies were halted
atmidterm, although a phase 1/2a study in thoracic SCI
(n = 12)was successfully completed.No reportsofpost-
termination follow-up were found. The aftermath of
these discontinued stem cell trials may be a deterrent
toward(1)newinvestments intoscientificallysoundtrials
and (2) equipoise for ongoing stem cell tourism toward
unproven treatments.4
Regulatory approval of trials depends on detailed
evaluation of the risk-benefit relationship for the pa-
tient.Subsequentprotocolchanges initiatedbyanyparty
maynot shift the risk-benefit relationship to less than fa-
vorable. Premature study termination jeopardizes ac-
quisition of knowledge. This in turn affects the benefit-
risk ratio, which was calculated initially based on the
assumption that the studywould deliver on the task of
optimal knowledge gain in a new frontier of research.
On theotherhand, industry sponsors, takingup the
challenge of translational research and early therapeu-
tic development, inevitably need to have some means
to deviate from original plans while also responding to
vital business considerations. This is made possible if
companies can rely on the opportunity to unilaterally
decide for early termination or even corporate dissolu-
tion. To restrict sponsors’ ability to enforce such man-
agement decisions5 would likely have a negative long-
termeffecton interventional trials,with further lowered
appeal to invest in anorphan-like condition (eg, SCI), re-
sulting in impeded translation of new therapies.
Sponsorsoftendependonfutilityanalysestotestthe
ability of a trial to achieve its objectives (ie, effective-
ness) inconsiderationofearlytermination(ornot).6How-
ever, applied toearlyphase 1/2a trials, thevalidityofa fu-
tility analysis is compromised by insufficient statistical
power, sometimes lower than the predictive power of a
coin toss (50%) to detect even large effects. Early and
underpowered futility decisions also abrogate the pre-
cious opportunity to address important secondary re-
search questions (ie, patient stratification and second-
ary efficacy measures) that provide additional disease
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Suspended/terminated trials predominate the field of spinal cord
injury stem cell transplantation (n = 7 of 15) in North America and
Europe and pose the question on how academia and the
pharmaceutical industry canwork togethermore effectively. The
provision of an exit plan covering the follow-up examinations of all
patients enrolled until the termination date needs to bemade
obligatory for trial approval. Translation of basic and preclinical
stem cell research efforts will be evenmore difficult in the future
given the premature termination of prominent spinal cord injury
early-phase trials owing to futility analysis underpowered to reveal
efficacy. Discontinued stem cell trials in spinal cord injury
demarcate an interim burial mound located in the “valley of death”
spanning frombasic/preclinical to clinical research and neglects
the opportunity to improve the conduct of future stem cell studies
through investigation of secondary end points.
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and/or therapy insights. Decisions to discontinue therapeutic expo-
sure if there are adverse effects with no benefits or subtle benefits
outweighed by harm should be the responsibility of a data safety
monitoring board independent from futility analysis or strategic
decisions.
When a well-justified decision to terminate a clinical research
study is reached,5,7 it is imperative that the sponsor (corporate,
governmental, or university) continues to ensure follow-up clinical
evaluations for all participants who have entered the trial. Aban-
doned follow-up (1) ultimately results in “poor science” (eg, incom-
plete data sets) and (2) harms the doctor-researcher/patient rela-
tionship. Requiring sponsors to guarantee sufficient funds upfront
to safeguard follow-up for each patient can negate this.
As the International Council for Harmonization remains silent
on the financial responsibility of sponsors to provide follow-up af-
ter early termination of a trial, we advocate for the linkage of ap-
proval of future trials by regulatory authorities with an a priori or-
derly exit strategy. Clinical investigators remain bound by the
Hippocratic Oath, which orders physicians to keep patients from
harm and injustice even if their institution is unable or unwilling to
bear the costs of early termination of sponsored trials. In the case
of the early termination of Stem Cells Inc Human Central Nervous
System Stem Cells Phase 2 cervical trial, no resources were pro-
vided for a final study termination visit, even in patients whowere
just a fewweeks post–cell transplantation.
Premature termination of a clinical trial without an orderly
closure plan is a threat to the trust of patient volunteers and clini-
cal investigators who feel bound to their patients and by the Hip-
pocratic Oath. Discussions with regulatory agencies are war-
ranted to ensure that the financial and ethical burden of early
termination is appropriately balanced to ensure the well-being of
patient volunteers.
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